MacroGenics IncNASDAQ:MGNX
- LAST PRICE4.3350
- TODAY'S CHANGE (%)-0.0300 (-0.6873%)
- Bid / Lots4.3300/ 8
- Ask / Lots4.3400/ 11
- Open / Previous Close4.4300 / 4.3650
- Day Range
- 52 Week Range
- Volume1,058,556
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MGNX |
|---|---|---|
| 09:32 ET | 84532 | 4.3699 |
| 09:34 ET | 16145 | 4.36 |
| 09:36 ET | 28928 | 4.29 |
| 09:38 ET | 12714 | 4.2999 |
| 09:39 ET | 9434 | 4.2988 |
| 09:41 ET | 14032 | 4.2951 |
| 09:43 ET | 8932 | 4.28 |
| 09:45 ET | 5737 | 4.31 |
| 09:48 ET | 3247 | 4.34 |
| 09:50 ET | 3466 | 4.3297 |
| 09:52 ET | 4209 | 4.33 |
| 09:54 ET | 4607 | 4.35 |
| 09:56 ET | 11556 | 4.3697 |
| 09:57 ET | 28812 | 4.36 |
| 09:59 ET | 26919 | 4.31 |
| 10:01 ET | 16304 | 4.34 |
| 10:03 ET | 30059 | 4.34 |
| 10:06 ET | 4062 | 4.34 |
| 10:08 ET | 6274 | 4.275 |
| 10:10 ET | 85499 | 4.1401 |
| 10:12 ET | 34170 | 4.235 |
| 10:14 ET | 22678 | 4.2885 |
| 10:15 ET | 30261 | 4.3001 |
| 10:17 ET | 68524 | 4.31 |
| 10:19 ET | 17007 | 4.3019 |
| 10:21 ET | 24210 | 4.305 |
| 10:24 ET | 58638 | 4.2625 |
| 10:26 ET | 7559 | 4.2388 |
| 10:28 ET | 24810 | 4.22 |
| 10:30 ET | 9993 | 4.215 |
| 10:32 ET | 9575 | 4.24 |
| 10:33 ET | 807 | 4.25 |
| 10:35 ET | 11834 | 4.3 |
| 10:37 ET | 6008 | 4.32 |
| 10:39 ET | 4889 | 4.316 |
| 10:42 ET | 1402 | 4.32 |
| 10:44 ET | 4326 | 4.29 |
| 10:46 ET | 1502 | 4.285 |
| 10:48 ET | 2300 | 4.2801 |
| 10:50 ET | 7911 | 4.285 |
| 10:51 ET | 1003 | 4.285 |
| 10:53 ET | 4581 | 4.28 |
| 10:55 ET | 4894 | 4.29 |
| 10:57 ET | 443 | 4.295 |
| 11:00 ET | 5863 | 4.295 |
| 11:02 ET | 281 | 4.2901 |
| 11:04 ET | 4383 | 4.2912 |
| 11:06 ET | 446 | 4.295 |
| 11:08 ET | 200 | 4.295 |
| 11:09 ET | 6266 | 4.285 |
| 11:11 ET | 7915 | 4.2708 |
| 11:13 ET | 8508 | 4.28 |
| 11:15 ET | 1800 | 4.28 |
| 11:18 ET | 8258 | 4.285 |
| 11:20 ET | 8893 | 4.276 |
| 11:22 ET | 3771 | 4.28 |
| 11:24 ET | 2265 | 4.28 |
| 11:26 ET | 38016 | 4.3212 |
| 11:27 ET | 1585 | 4.33 |
| 11:29 ET | 1255 | 4.32 |
| 11:31 ET | 2812 | 4.32 |
| 11:33 ET | 3402 | 4.3 |
| 11:36 ET | 4905 | 4.291 |
| 11:38 ET | 2352 | 4.3 |
| 11:40 ET | 1301 | 4.3 |
| 11:42 ET | 300 | 4.3 |
| 11:44 ET | 4414 | 4.3112 |
| 11:45 ET | 3154 | 4.34 |
| 11:47 ET | 2508 | 4.345 |
| 11:49 ET | 300 | 4.345 |
| 11:51 ET | 2100 | 4.345 |
| 11:54 ET | 36954 | 4.335 |
| 11:56 ET | 13067 | 4.335 |
Today
Yesterday
May 18, 2024
IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against MacroGenics, Inc. and Encourages Investors to Contact the Firm, from 11:01AM ET on Saturday May 18, 2024 by Dow Jones
11:01AM ET on Saturday May 18, 2024 by Dow JonesSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MacroGenics, Inc. - MGNX, from 8:16AM ET on Saturday May 18, 2024 by Dow Jones
8:16AM ET on Saturday May 18, 2024 by Dow Jones
May 17, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
MacroGenics Inc | 273.1M | -11.5x | --- |
Adaptimmune Therapeutics PLC | 283.7M | -1.4x | --- |
Innate Pharma SA | 211.7M | -26.7x | --- |
Poseida Therapeutics Inc | 309.3M | -2.8x | --- |
Codexis Inc | 254.7M | -3.7x | --- |
Metagenomi Inc | 262.3M | -3.8x | --- |
Company Information
MacroGenics, Inc. is a biopharmaceutical company focused on developing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. It generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is vobramitamab duocarmazine (vobra duo), an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Its clinical pipeline includes two product candidates based on its, bispecific DART technology that co-engages both PD-1 and other checkpoint molecules. These candidates include lorigerlimab and tebotelimab. In addition, it is developing MGD024, a bispecific DART molecule. It is also developing various other programs.
Contact Information
- Headquarters
- 9704 Medical Center DriveROCKVILLE, MD, United States 20850
- Phone
- 301-251-5172
- Fax
- 301-251-5321
Executives
- Independent Chairman of the Board
- William Heiden
- President, Chief Executive Officer, Director
- Scott Koenig
- Chief Financial Officer, Senior Vice President, Corporate Secretary
- James Karrels
- Chief Operating Officer
- Eric Risser
- Senior Vice President - Research, Chief Scientific Officer
- Ezio Bonvini
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $273.1M |
|---|---|
Revenue (TTM) | $43.4M |
Shares Outstanding | 62.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.98 |
EPS | $-0.38 |
Book Value | $2.46 |
P/E Ratio | -11.5x |
Price/Sales (TTM) | 6.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -75.28% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
